RT Journal Article SR Electronic T1 Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA518 DO 10.1183/13993003.congress-2016.PA518 VO 48 IS suppl 60 A1 Saoussen Bacha A1 Sabrine Mejdoub A1 Amani Sghaier A1 Habibach Sonia A1 Hager Racil A1 Sana Cheikhrouhou A1 Naouel Chaouch A1 Abdellatif Chabbou A1 Mohamed Lamine Megdiche YR 2016 UL http://erj.ersjournals.com/content/48/suppl_60/PA518.abstract AB Background: Systemic inflammation has been shown to be responsible of tumor growth and shortened survival. Advanced lung cancer inflammation index (ALI) was developed to assess inflammation and prognostic in lung cancer at the time of diagnosis. Therefore, the aim of this study was to explore the relationship between ALI and the prognosis of NSCLC.Methods: Patients diagnosed with stage IV NSCLC at our institution between janv 2010 and janv 2013 were screened. ALI score was calculated as BMIxALB/NLR with BMI=body mass index, Alb=serum albumin and NLR=neutrophil lymphocyte ratio. Patients were divided into low inflammation (ALI>18) and high inflammation (ALI<18). Chi-squared test was performed to compare clinical characteristics in different groups. Kaplan-Meier and Cox regression model were used to determine independent prognostic factors.Results Fifty eight patients were included. Median age was 61 years, all patients were male and 48.7 % had adenocarcinoma. Compared to patients with ALI score>18, Patients with ALI score <18 had a poor PS (p=0.006) and were less likely to receive chemotherapy (p=0.003). Median overall survival (OS) was 6.7month and month as opposed to11.3 month in patients with ALI>18 (p=0.043). On multivariate analysis, Performans status (p=0.006), CRP (p=0.007), receiving chemotherapy (p=0.003) and ALI score (HR=2.38; IC95% [1.00-5.67]; p=0.049) were independent prognostic factors for OS.Conclusion: ALI is an easy to calculate tool to assess systemic inflammation in advanced NSCLC. Lower ALI could authenticate the patients with poor prognosis and be a useful marker in clinical practice.